Skip to content

Molecular Characterization of Candida Auris

Formulation Development and In-Vitro Studies of Efficacy of Botanical Extracts Against Candida Auris

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04121871
Acronym
OC
Enrollment
384
Registered
2019-10-10
Start date
2019-11-15
Completion date
2020-02-29
Last updated
2020-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Fungal Infection

Keywords

Candida auris, Oral Fungal Infection, Candidiasis

Brief summary

Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat. Our hypothesis is that by recording the patients diagnosed with oropharygneal candidiasis and collecting clinical swab samples from these patients will be fruitful if microbiological isolation, identification and molecular characterization will be done. So this is the first study on C. auris in south punjab, Pakistan. Aim of this study is to collect epidemiological data of C. auris.

Interventions

OTHERNo intervention

Not required

Sponsors

Islamia University of Bahawalpur
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 100 Years
Healthy volunteers
No

Inclusion criteria

* Pre-diagnosed Patients of both gender from pre-selected localities

Exclusion criteria

* Healthy individuals or individuals having no oral fungal infection individuals above 100 years of age

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of C. aurisFrom November 15, 2019 to February 29, 2020patients from selected localities will be recorded along with total patients in that category, prevalence will be calculated on the record collected from specified duration of study
Seasonality of C. auris infectionFrom November 15, 2019 to February 29, 2020Number of patients recorded during different months will be the source of calculation of seasonality index of the C. auris infection
Drug susceptibilityFrom November 15, 2019 to February 29, 2020Antifungal drug discs will be used for assessing the antfungal drugs susceptibility

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026